Steroids a double-edged sword

Article

Corticosteroids are a valuable therapeutic modality in the management of a variety of ocular diseases, but their potential to cause serious adverse events make judicious prescribing critical.

Corticosteroids are a valuable therapeutic modality in the management of a variety of ocular diseases, but their potential to cause serious adverse events makes judicious prescribing critical, according to Bruce Onofrey, RPh, OD.

Proper diagnosis, selection of the appropriate steroid, and careful monitoring for adverse events are fundamental for staying on the benefit side of the equation, he added.

While steroids are appropriate treatment for many clinical scenarios, there are some instances in which they are relatively contraindicated. Some of the major uses for steroids are in the management of patients who have undergone cataract or laser refractive surgery and to control inflammation and prevent tissue damage in eyes with uveitis, ocular surface disease, certain infections, and allergy.

In laser refractive surgery patients, steroids are an important component in the medication regimen used after PRK as studies show their benefit for preventing corneal haze and regression of the refractive effect.

The major purpose for using a steroid in cataract surgery patients is to prevent the release of inflammatory mediators that can lead to the development of cystoid macular edema (CME). This is particularly important in diabetics who are more prone to develop postoperative CME and who may require a longer duration of treatment.

Management of non-granulomatous anterior uveitis is another common use of steroids. Efficacy requires aggressive treatment with frequent dosing and a long enough duration, followed by a slow taper.

"Initially, topical steroid treatment for anterior uveitis may require hourly instillation. As the inflammation is controlled, the tapering period can last up to 1 month," Dr. Onofrey said.

Managing inflammation in OSD

For the management of ocular surface disease, steroids help reduce inflammation that causes ocular surface and lacrimal gland damage. However, they should only be used short-term for 2 to 4 weeks.

"Topical cyclosporine (Restasis, Allergan) is the drug of choice for maintenance anti-inflammatory therapy in inflammatory dry eye disease. However, a steroid can be used in a pulse or intermittent regimen as needed as long as the patient is carefully monitored for side effects, including IOP elevation and secondary infection, particularly herpetic infection," he said.

Steroids may also be beneficial in the management of inflammatory blepharitis, but again, you must be careful that patients do not continue the treatment long-term.

"Better options for managing inflammatory blepharitis include good lid hygiene, omega-3 fatty acid supplementation, and if necessary, low-dose oral doxycycline," he said.

Indications for infections

Infections in which steroids are indicated include adenoviral epidemic keratoconjunctivitis. In this condition, steroids are indicated for treating pseudomembranes and for preventing the development of corneal opacification and ocular surface disease arising from inflammatory damage to the lacrimal glands.

Steroids also have a critical role in treating herpes zoster ophthalmicus and for managing keratitis associated with herpes simplex virus infection.

"However, steroids must be avoided in suspected cases of epithelial herpetic disease or where fungal keratitis is a possibility," Dr. Onofrey said.

Recent Videos
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.
Susan Gromacki, OD, FAAO, FSLS, provides key takeaways from this year's American Academy of Optometry symposium genetics and the cornea.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
© 2024 MJH Life Sciences

All rights reserved.